Free Trial
NASDAQ:BJDX

Bluejay Diagnostics 11/9/2023 Earnings Report

Bluejay Diagnostics logo
$2.14 +0.59 (+38.06%)
Closing price 04:00 PM Eastern
Extended Trading
$2.10 -0.04 (-2.10%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bluejay Diagnostics EPS Results

Actual EPS
-$832.00
Consensus EPS
-$328.00
Beat/Miss
Missed by -$504.00
One Year Ago EPS
N/A

Bluejay Diagnostics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bluejay Diagnostics Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bluejay Diagnostics' next earnings date is estimated for Thursday, November 6, 2025, based on past reporting schedules.

Conference Call Resources

Bluejay Diagnostics Earnings Headlines

An $8 trillion-dollar discovery 17,000 ft underwater
A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materials critical for AI chips, EV batteries, smartphones, and advanced weapons systems. While few people know about these metals, global powers—including the U.S., China, and Russia—are racing to secure them. And one tiny public company, recently backed by the U.S. government, holds mining rights to over 340 million tons… and near-monopoly access to the richest zone.tc pixel
See More Bluejay Diagnostics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bluejay Diagnostics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bluejay Diagnostics and other key companies, straight to your email.

About Bluejay Diagnostics

Bluejay Diagnostics (NASDAQ:BJDX) (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting. The company has been pursuing clinical validation studies and regulatory clearances to support its plans for commercialization, working to demonstrate accuracy, reliability, and ease of use in both clinical and at-home environments.

Headquartered in Norcross, Georgia, Bluejay Diagnostics serves the U.S. market with strategic plans to expand internationally once regulatory approvals and distribution partnerships are in place. The management team brings together expertise in diagnostics, biotech development, and regulatory affairs, positioning the company to navigate the complex pathways associated with medical device registration and market entry. As Bluejay advances its development pipeline, it aims to improve patient access to timely, accurate, and patient-friendly diagnostic solutions for celiac disease and related disorders.

View Bluejay Diagnostics Profile

More Earnings Resources from MarketBeat